Iodine-125-MIBG to treat neuroblastoma: Preliminary report

J. C. Sisson; R. J. Hutchinson; B. Shapiro; K. R. Zasadny; D. Normolle; D. M. Wieland; R. L. Wahl; D. A. Singer; S. A. Mallette; E. E. Mudgett

Iodine-125-MIBG to treat neuroblastoma: Preliminary report

J. C. Sisson, R. J. Hutchinson, B. Shapiro, K. R. Zasadny, D. Normolle, D. M. Wieland, R. L. Wahl, D. A. Singer, S. A. Mallette, E. E. Mudgett

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Three children with Stage III neuroblastoma were treated with [¹²⁵I]MIBG in a phase I toxicity study. Concepts of the treatment were: in small tumors, the absorbed dose of radiation from MIBG labeled with ¹³¹I is reduced but the absorbed dose from [¹²⁵I]MIBG is less affected; and many recurrences of neuroblastoma arise from small tumors. Two patients exhibited only modest thrombocytopenia and leukopenia, the most sensitive indices of radiation toxicity, after receiving 261 and 407 mCi, and 83 and 104 rad of whole-body radiation. One patient died of progressive neuroblastoma; the other two patients have stable disease over 30 mo after treatment. Per millicurie given, [¹²⁵I]MIBG imparts about one-fourth the radiation dose of [¹³¹I]MIBG to the whole body. Iodine-125-MIBG can be given in doses that impart over 100 rad of whole-body radiation and that exceed 400 mCi before toxicity becomes limiting, even in small children.

Original language	English (US)
Pages (from-to)	1479-1485
Number of pages	7
Journal	Journal of Nuclear Medicine
Volume	31
Issue number	9
State	Published - 1990
Externally published	Yes

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Cite this

@article{85415ce736f8430489bf289907891da9,

title = "Iodine-125-MIBG to treat neuroblastoma: Preliminary report",

abstract = "Three children with Stage III neuroblastoma were treated with [125I]MIBG in a phase I toxicity study. Concepts of the treatment were: in small tumors, the absorbed dose of radiation from MIBG labeled with 131I is reduced but the absorbed dose from [125I]MIBG is less affected; and many recurrences of neuroblastoma arise from small tumors. Two patients exhibited only modest thrombocytopenia and leukopenia, the most sensitive indices of radiation toxicity, after receiving 261 and 407 mCi, and 83 and 104 rad of whole-body radiation. One patient died of progressive neuroblastoma; the other two patients have stable disease over 30 mo after treatment. Per millicurie given, [125I]MIBG imparts about one-fourth the radiation dose of [131I]MIBG to the whole body. Iodine-125-MIBG can be given in doses that impart over 100 rad of whole-body radiation and that exceed 400 mCi before toxicity becomes limiting, even in small children.",

author = "Sisson, {J. C.} and Hutchinson, {R. J.} and B. Shapiro and Zasadny, {K. R.} and D. Normolle and Wieland, {D. M.} and Wahl, {R. L.} and Singer, {D. A.} and Mallette, {S. A.} and Mudgett, {E. E.}",

year = "1990",

language = "English (US)",

volume = "31",

pages = "1479--1485",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "9",

}

TY - JOUR

T1 - Iodine-125-MIBG to treat neuroblastoma

T2 - Preliminary report

AU - Sisson, J. C.

AU - Hutchinson, R. J.

AU - Shapiro, B.

AU - Zasadny, K. R.

AU - Normolle, D.

AU - Wieland, D. M.

AU - Wahl, R. L.

AU - Singer, D. A.

AU - Mallette, S. A.

AU - Mudgett, E. E.

PY - 1990

Y1 - 1990

N2 - Three children with Stage III neuroblastoma were treated with [125I]MIBG in a phase I toxicity study. Concepts of the treatment were: in small tumors, the absorbed dose of radiation from MIBG labeled with 131I is reduced but the absorbed dose from [125I]MIBG is less affected; and many recurrences of neuroblastoma arise from small tumors. Two patients exhibited only modest thrombocytopenia and leukopenia, the most sensitive indices of radiation toxicity, after receiving 261 and 407 mCi, and 83 and 104 rad of whole-body radiation. One patient died of progressive neuroblastoma; the other two patients have stable disease over 30 mo after treatment. Per millicurie given, [125I]MIBG imparts about one-fourth the radiation dose of [131I]MIBG to the whole body. Iodine-125-MIBG can be given in doses that impart over 100 rad of whole-body radiation and that exceed 400 mCi before toxicity becomes limiting, even in small children.

AB - Three children with Stage III neuroblastoma were treated with [125I]MIBG in a phase I toxicity study. Concepts of the treatment were: in small tumors, the absorbed dose of radiation from MIBG labeled with 131I is reduced but the absorbed dose from [125I]MIBG is less affected; and many recurrences of neuroblastoma arise from small tumors. Two patients exhibited only modest thrombocytopenia and leukopenia, the most sensitive indices of radiation toxicity, after receiving 261 and 407 mCi, and 83 and 104 rad of whole-body radiation. One patient died of progressive neuroblastoma; the other two patients have stable disease over 30 mo after treatment. Per millicurie given, [125I]MIBG imparts about one-fourth the radiation dose of [131I]MIBG to the whole body. Iodine-125-MIBG can be given in doses that impart over 100 rad of whole-body radiation and that exceed 400 mCi before toxicity becomes limiting, even in small children.

UR - http://www.scopus.com/inward/record.url?scp=0025091505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025091505&partnerID=8YFLogxK

M3 - Article

C2 - 2395016

AN - SCOPUS:0025091505

SN - 0161-5505

VL - 31

SP - 1479

EP - 1485

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 9

ER -

Iodine-125-MIBG to treat neuroblastoma: Preliminary report

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this